Pexidartinib hydrochloride is primarily used in the treatment of tenosynovial giant cell tumor (TGCT), a rare and often debilitating condition affecting the joints and tendons. It is specifically indicated for cases where surgery is not a viable option due to the tumor's location or potential for severe functional impairment. The compound works by inhibiting colony-stimulating factor 1 receptor (CSF1R), which plays a key role in the growth and survival of the abnormal cells driving TGCT. By targeting this receptor, pexidartinib hydrochloride helps reduce tumor size and alleviate symptoms such as pain and stiffness, improving patients' quality of life. It is administered orally, offering a non-invasive treatment option for eligible patients. However, due to potential liver toxicity, its use is closely monitored, and patients undergo regular liver function tests during therapy.